Monoclonal Antibody Prevents Malaria in U.S. Adults, NIH Trial Shows

One injection of a candidate monoclonal antibody (mAb) known as L9LS was found to be safe and highly protective in U.S. adults exposed to the malaria parasite, according to results from a National Institutes of Health Phase 1 clinical trial published in The New England Journal of Medicine.

Contact

Submit a Media Request

Contact the NIAID News & Science Writing Branch.

301-402-1663
niaidnews@niaid.nih.gov
All Media Contacts

Vaccine Targeting Mosquito-Borne Viruses Safely Prompts Immune Response in Clinical Trial

Dr. Kumar Receives Two NIH Grants to Study Bacterial and Viral Infections of the Eye

Publish or Event Date
Research Institution
The Wayne State University School of Medicine
Short Title
Dr. Kumar Receives Two NIH Grants to Study Bacterial and Viral Infections of the Eye
Content Coordinator

Consortium Formed to Discover Antivirals for COVID-19 Receives NIH Funding to Develop Globally Accessible Treatments for Pandemics

Publish or Event Date
Research Institution
DNDi
Short Title
Consortium Formed to Discover Antivirals for COVID-19 Receives NIH Funding to Develop Globally Accessible Treatments for Pandemics
Content Coordinator

UCSF Awarded $67.5 Million to Develop New Antiviral Therapies

Scripps Research Awarded $67 Million by NIH to Lead New Pandemic Preparedness Center

Unexpected Antibody Type Found in People with Malaria Infections

Media Type
Article
Publish or Event Date
Research Institution
University of Maryland School of Medicine
Short Title
Unexpected Antibody Type Found in People with Malaria Infections
Content Coordinator
Content Manager

Blocking How the Malaria Parasite Suppresses the Immune Response

Revolutionary Mosquito Researchers Receive $2.7 Million Grant

Mapping Dengue Hot Spots Pinpoints Risks for Zika and Chikungunya